Physician profile
Tara Olsen
NPI 1235827213
$1,271.04
in general payments reported to CMS, 2019-2025
26 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $485 · 2024: $667 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $245.87 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $199.32 | 2023-2024 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $93.15 | 2023-2024 | Trelegy Ellipta |
| Medtronic, INC. | $63.23 | 2024 | Interstim |
| Abbvie INC. | $57.08 | 2023 | |
| Ironwood Pharmaceuticals, INC | $52.88 | 2023-2024 | Linzess |
| Exact Sciences Corporation | $51.86 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.64 | 2023-2024 | Jardiance |
| Amgen INC. | $47.80 | 2024 | Repatha, Otezla |
| Novo Nordisk INC | $45.76 | 2023-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $44.67 | 2023-2025 | Mounjaro, Zepbound |
| Eisai INC. | $44.37 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $32.01 | 2024-2025 | |
| Kerecis Limited | $30.62 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Mimedx Group, INC. | $26.02 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $21.49 | 2025 | Phasix Mesh |
| Merck Sharp & Dohme LLC | $20.02 | 2024 | Recarbrio, Zerbaxa, Dificid |
| Olympus America INC. | $19.75 | 2025 | Olympus |
| Solventum Corporation | $19.02 | 2024 | Bair Hugger, V.A.C.Ulta, V.A.C.Instill |
| Teleflex LLC | $18.81 | 2025 | Titan Sgs Bailout Chuck |
| Novartis Pharmaceuticals Corporation | $16.83 | 2024 | |
| Radius Health, INC. | $15.69 | 2023 | Tymlos |
| Pfizer INC. | $14.69 | 2023 | |
| Mylan Specialty L.P. | $14.10 | 2024 | Yupelri |
| Ultragenyx Pharmaceutical INC. | $13.60 | 2023 | Crysvita |
| Scilex Pharmaceuticals INC. | $12.76 | 2023 | Ztlido |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.